MILWAUKEE, Aug. 5, 2025 /PRNewswire/ -- The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.  There is no cost or obligation to you.In the tender offer transaction, shareholders of Y-mAbs will receive $$8.60 per share in cash, representing approximat ...